Instituto Universitario de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, Valladolid, Spain.
Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS-REI), Inflamación E Inmunopatologia de Organos y Sistemas, Instituto de Salud Carlos III, Valladolid, Spain.
Stem Cell Res Ther. 2024 Jul 2;15(1):192. doi: 10.1186/s13287-024-03804-2.
Inherited retinal dystrophies (IRD) are one of the main causes of incurable blindness worldwide. IRD are caused by mutations in genes that encode essential proteins for the retina, leading to photoreceptor degeneration and loss of visual function. IRD generates an enormous global financial burden due to the lack of understanding of a significant part of its pathophysiology, molecular diagnosis, and the near absence of non-palliative treatment options. Patient-derived induced pluripotent stem cells (iPSC) for IRD seem to be an excellent option for addressing these questions, serving as exceptional tools for in-depth studies of IRD pathophysiology and testing new therapeutic approaches.
From a cohort of 8 patients with PROM1-related IRD, we identified 3 patients carrying the same variant (c.1354dupT) but expressing three different IRD phenotypes: Cone and rod dystrophy (CORD), Retinitis pigmentosa (RP), and Stargardt disease type 4 (STGD4). These three target patients, along with one healthy relative from each, underwent comprehensive ophthalmic examinations and their genetic panel study was expanded through clinical exome sequencing (CES). Subsequently, non-integrative patient-derived iPSC were generated and fully characterized. Correction of the c.1354dupT mutation was performed using CRISPR/Cas9, and the genetic restoration of the PROM1 gene was confirmed through flow cytometry and western blotting in the patient-derived iPSC lines.
CES revealed that 2 target patients with the c.1354dupT mutation presented monoallelic variants in genes associated with the complement system or photoreceptor differentiation and peroxisome biogenesis disorders, respectively. The pluripotency and functionality of the patient-derived iPSC lines were confirmed, and the correction of the target mutation fully restored the capability of encoding Prominin-1 (CD133) in the genetically repaired patient-derived iPSC lines.
The c.1354dupT mutation in the PROM1 gene is associated to three distinct AR phenotypes of IRD. This pleotropic effect might be related to the influence of monoallelic variants in other genes associated with retinal dystrophies. However, further evidence needs to be provided. Future experiments should include gene-edited patient-derived iPSC due to its potential as disease modelling tools to elucidate this matter in question.
遗传性视网膜营养不良(IRD)是全球范围内导致不可治愈失明的主要原因之一。IRD 是由编码视网膜必需蛋白的基因突变引起的,导致光感受器变性和视觉功能丧失。由于对其病理生理学、分子诊断的很大一部分以及几乎没有非姑息性治疗选择缺乏了解,IRD 给全球带来了巨大的经济负担。IRD 患者来源的诱导多能干细胞(iPSC)似乎是解决这些问题的绝佳选择,可作为深入研究 IRD 病理生理学和测试新治疗方法的绝佳工具。
我们从一组 8 名 PROM1 相关 IRD 患者中确定了 3 名携带相同变体(c.1354dupT)但表现出三种不同 IRD 表型的患者: cones 和 rods 营养不良(CORD)、色素性视网膜炎(RP)和 Stargardt 病 4 型(STGD4)。这 3 名目标患者,以及每位患者的一位健康亲属,接受了全面的眼科检查,并通过临床外显子组测序(CES)扩展了他们的基因panel 研究。随后,生成了非整合型患者来源的 iPSC,并对其进行了全面表征。使用 CRISPR/Cas9 对 c.1354dupT 突变进行校正,并通过流式细胞术和 Western blot 在患者来源的 iPSC 系中确认 PROM1 基因的遗传修复。
CES 显示,携带 c.1354dupT 突变的 2 名目标患者分别存在与补体系统或光感受器分化和过氧化物酶体生物发生障碍相关的基因的单等位基因变异。患者来源的 iPSC 系的多能性和功能得到了确认,目标突变的校正完全恢复了基因修复后的患者来源的 iPSC 系中编码 Prominin-1(CD133)的能力。
PROM1 基因中的 c.1354dupT 突变与 3 种不同的 AR 型 IRD 表型相关。这种多效性效应可能与其他与视网膜营养不良相关的基因中的单等位基因变异有关。然而,需要提供更多证据。未来的实验应该包括基因编辑的患者来源的 iPSC,因为它具有作为疾病建模工具的潜力,可以阐明这一问题。